Skip to main content
Equibles
RCKT logo

RCKT · Rocket Pharmaceuticals, Inc.

Track RCKT — free

Use RCKT with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about RCKT

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.48 -0.17 (-4.66%) At close · Aug 20
Market Cap
$377.62M
Shares
109.77M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.48 Open$3.60 Day$3.43–3.66 52W close$2.60–5.30 Avg vol 30d1.5M Short int15.5M · 14.1% float · 11.9d Short vol60% Last earningsMar 27, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 10

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 10, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Buy Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.9 · calm Equity put/call 0.52
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg −2%
below
Price vs 50-day avg +2%
above
RSI (14) 51
neutral
MACD trend Positive
52-week position 33%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +6%
trailing
6-month return −31%
trailing
YTD return −1%
this year
Relative strength −42%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow Distributing
-8% holders QoQ · +23 funds added
Insider flow Distributing
Net -$176.0K over 90 days · 100% sells
Short interest Falling
14.12% of float · ▼ -6.5% MoM · 11.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
184 holders — mid 3-yr range
Squeeze score 72
high risk · 0–100
Fundamentals
Strong
EPS growth +26%
Y/Y
Free cash flow $-190.5M
Balance sheet $77.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 71%
annualized · 1-yr
Max drawdown −51%
past year
ATR 5.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 5 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−2% Neutral
Price vs 50-day avg
+2% Bullish
RSI (14)
51 Neutral
MACD trend
Positive Bullish
52-week position
33% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow Distributing
-8% holders QoQ · +23 funds added
Insider flow Distributing
Net -$176.0K over 90 days · 100% sells
Short interest Falling
14.12% of float · ▼ -6.5% MoM · 11.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
184 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3 Now $3 · 33% Range high $5
vs 200-day avg -2% vs 50-day avg +2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Pro forma cash, cash equivalents and investments $322.6M Q1 2026 —
Rare Pediatric Disease Priority Review Voucher monetization $180M Q1 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RCKT
Rocket Pharmaceuticals, Inc.
this stock
$377.62M -0.9% — — 14.1%
ONC
BeOne Medicines Ltd.
 $557.05B +21.5% +22179.2% 856.5 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $136.93B +19.2% +46.2% 31.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $86.39B +7.1% +20.8% 20.8 3.3%
MRNA
Moderna, Inc.
 $69.62B +352.1% +4.3% — 12.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
184
% held
92.6%
Net QoQ
+4.0M sh
Top holder
RTW INVESTMENTS, LP
Held Float
View
Held by Funds
Fund positions
168
View
Short & Settlement
Short Interest Falling
Shares short
15.5M
Days to cover
11.9d
Change
-1.1M sh
View
Short Volume
Short vol %
60%
As of
Aug 20, 2026
Short Total
View
Fails to Deliver
FTD shares
1.3K
Value
$4.2K
As of
Jul 30, 2026
View
Off-Exchange
Off-exchange %
47.9%
Week of
Jul 13, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$176.0K
Buyers / Sellers
0 / 4
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-223.1M
EPS diluted
$-2.01
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 10, 2026
This year
17
View
Proposed Sales
Value
$7.8K
Shares
2.3K
Filed
Aug 18, 2026
View
Earnings & Events
Earnings Calls
Last call
Jun 9, 2026
View
Investor Relations
Latest news
Rocket Pharmaceuticals Reports Se…
Published
Aug 10, 2026
View

Performance

5D 20D 120D MTD YTD
RCKT +4.2% +6.1% -30.5% +11.9% -0.9%
SPY -2.0% +3.3% +11.2% +2.1% +11.8%
vs SPY +6.2% +2.8% -41.7% +9.8% -12.7%
Key facts CIK 1281895 CUSIP 77313F106 13F (30d) 172 filings 170 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)